FY2025 EPS Estimates for MNMD Cut by Cantor Fitzgerald

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Mind Medicine (MindMed) in a report released on Wednesday, May 21st. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn ($1.53) per share for the year, down from their previous forecast of ($1.39). Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

A number of other equities analysts also recently issued reports on the company. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research note on Friday, May 9th. Evercore ISI initiated coverage on Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They set an “outperform” rating and a $23.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Mind Medicine (MindMed) in a research note on Friday, March 7th. Finally, Robert W. Baird cut their target price on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, March 7th. Nine equities research analysts have rated the stock with a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, Mind Medicine (MindMed) has a consensus rating of “Buy” and an average target price of $25.11.

Mind Medicine (MindMed) Stock Up 3.3%

MNMD opened at $7.30 on Friday. The business has a 50 day moving average price of $6.20 and a two-hundred day moving average price of $6.98. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09. The company has a market cap of $550.19 million, a PE ratio of -3.23 and a beta of 2.52. Mind Medicine has a 52 week low of $4.70 and a 52 week high of $10.44.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.01.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Large investors have recently bought and sold shares of the stock. Diadema Partners LP acquired a new stake in Mind Medicine (MindMed) during the 4th quarter valued at $33,000. Hollencrest Capital Management grew its holdings in Mind Medicine (MindMed) by 10,833.3% during the 4th quarter. Hollencrest Capital Management now owns 7,216 shares of the company’s stock valued at $50,000 after buying an additional 7,150 shares during the last quarter. King Wealth Management Group acquired a new stake in Mind Medicine (MindMed) during the 4th quarter valued at $70,000. Virtus ETF Advisers LLC acquired a new stake in Mind Medicine (MindMed) during the 4th quarter valued at $70,000. Finally, Sharpepoint LLC acquired a new stake in Mind Medicine (MindMed) during the 4th quarter valued at $71,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Insider Buying and Selling

In related news, CEO Robert Barrow sold 21,208 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $142,941.92. Following the sale, the chief executive officer now owns 856,556 shares in the company, valued at $5,773,187.44. This represents a 2.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Daniel Karlin sold 6,836 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $46,074.64. Following the completion of the sale, the insider now owns 446,177 shares in the company, valued at approximately $3,007,232.98. This represents a 1.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,391 shares of company stock worth $204,835 in the last quarter. Company insiders own 2.45% of the company’s stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.